# TARGTEPO Treatment for Anemia in PD US Trial

> **NCT02468414** · PHASE2 · TERMINATED · sponsor: **Aevi Genomic Medicine, LLC, a Cerecor company** · enrollment: 3 (actual)

## Conditions studied

- Anemia of End Stage Renal Disease

## Interventions

- **BIOLOGICAL:** MDGN201 TARGTEPO
- **BIOLOGICAL:** MDGN201 TARGTEPO

## Key facts

- **NCT ID:** NCT02468414
- **Lead sponsor:** Aevi Genomic Medicine, LLC, a Cerecor company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due to the Sponsor's decision to discontinue study.
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02468414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02468414, "TARGTEPO Treatment for Anemia in PD US Trial". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02468414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*